Clinical Trial Update: Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating intravitreal ranibizumab for visual impairment due to macular edema from central retinal vein occlusion has completed and po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Retinal Vein Occlusion
• Macular Edema

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Macular Edema, Central Retinal Vein Occlusion | Phase 3 | Status: COMPLETED | Results posted: 2016-06-03